header logo image


Page 8«..78910..2030..»

Archive for April, 2020

‘Executioner protein’ discovery could lead to new eye disease therapeutics – Siliconrepublic.com

Sunday, April 26th, 2020

Researchers at Trinity have discovered a potential new therapeutic target for eye disease after studying the role of an executioner protein in retinal degeneration.

Research led by a team from Trinity College Dublin (TCD) has helped pinpoint a potential therapeutic target for a disease that affects thousands in Ireland.

While millions of people worldwide live with vision loss due to irreversible retinal degenerative diseases, its estimated that 5,000 people in Ireland inherit retinal degenerations, with a further 80,000 known to live with age-related macular degeneration (AMD).

This latest research, published to the journal Life Science Alliance, has revealed a protein called SARM1 that is involved in neuronal cell injury, but could also play a role in the progression of retinal degeneration.

Photoreceptor cells are specialised neurons found in the back of our eyes that convert light into electrical signals that allow us to see. It is the death of these cells, and the cells that nourish them, that is termed retinal degeneration and is characteristic of blinding diseases such as AMD and retinitis pigmentosa.

Researchers said this report is the first to describe a role for SARM1, referred to as the executioner protein, in photoreceptor cell biology.

Our research indicates that SARM1 is likely to be a key executioner in the process of retinal degeneration, because if we remove it from our experimental model system this has the effect of delaying the photoreceptor cells from dying, said Dr Sarah Doyle of the research team.

This is an important finding because the first steps involved in processing light into sight take place in the photoreceptors. As a result, losing photoreceptors ultimately equates to losing vision. For this reason, interventions that prevent or delay photoreceptor cell death are critical to preserve sight for as long as possible in people with degenerative retinal diseases.

The team was also able to show that the remaining photoreceptors maintained their function and continued to transmit electrical signals to the optic nerve.

This is particularly exciting for the future because others have recently shown that a gene therapy approach for inhibiting SARM1 is effective in protecting against neuronal degeneration, Doyle added.

We know that gene therapy is well suited as a treatment for retinal disease, so such an approach for inhibiting SARM1 activity may offer an option for protecting vision across multiple retinal degenerative diseases.

Go here to see the original:
'Executioner protein' discovery could lead to new eye disease therapeutics - Siliconrepublic.com

Read More...

How Space Travel Tries to Kill You and Make You Ugly – WIRED

Sunday, April 26th, 2020

Of these 34 risks, three are potential showstoppers: radiation, gravity (or lack thereof), and the need for surgery or a complicated medical procedure.

The Gravity of the Situation

Lets explore the gravity issue.

Some science fiction writers in the mid-20th century speculated that zero gravity would be life-giving: blood would flow more easily; arthritis would be a thing of the past; back pain would be cured for good; and aging itself would slow down. So, bring grandma along for the ride. We had hints from early in the space program that such a rosy scenario wasnt true. Astronauts returned from just a few days of weightlessness feeling weak. But they recovered; and many thought, well, maybe it isnt so bad. Then we spent more time in space. Russians on the Mir space station for months appeared to have some serious, prolonged health issues on their return. The Russians were tight-lipped about the health of their cosmonauts, though, so we never knew for sure. Many of these cosmonauts, championed as heroes, were rarely seen in public after their return. It was the ISS missions that drove home the message: long-term exposure to zero gravity is detrimental to human health on many levels. Kudos to NASA for that.

Before I continue, I should first define some terms. Zero gravity, however visually convenient, can be a misnomer in the context of near-earth activity. The astronauts on the ISS are not living in the absence of gravity. Rather, they are in free-fall, forever falling over the horizon and missing the Earth. The ISS and other satellites are not floating in space because they have escaped the pull of Earths gravity; they stay up there because of their terrific horizontal speed. The ISS is moving at 17,500 miles per hour. If, somehow, it came to a complete stop, it would fall straight down to Earth, and down would come astronaut, cradle and all. The Earths gravitational force, in fact, keeps the moving satellites in orbit as a perfectly balanced counterforce, in a downward motion, to the lateral motion set in place during the launch. Without the Earths gravitational force (if the Earth suddenly, magically, disappeared), the satellites would shoot off in a straight line. Therefore, more accurate terms for describing the lack of sensation of gravity aboard the ISS are microgravity and weightlessness. Yet, even these terms are neither perfect nor synonymous. Astronauts on the ISS have weight, about 90 percent of their weight on Earth, which is only about 200 miles below their feet. Theyd be much lighter on the Moon, actually, at just about 16 percent of their weight. Absolute zero gravity is not attainable, because gravity is the force of attraction between any two objects. But in deep space, far from the gravitational tug of any moon, planet, or star, gravity is attenuated to almost zero. I tend to use the terms zero gravity, micro-gravity, and weightlessness interchangeably in the context of space travel.

Our understanding of gravitys effect on the body has only two data points: one and zero. On Earth, we live with a gravitational force of 1G. On the ISS, astronauts live in 0G. We really dont know about anything in between. Air force pilots might accelerate their jets so quickly that they experience forces of 5G or higher, which sometimes causes them to black out. Thats five times the force of normal Earth gravity, which pushes blood out of their brains. But such forces typically last only a few seconds; the pilots arent living in a hyper-gravity environment. And anyway, we dont care too much about forces greater than 1G because every place we want to go in our Solar SystemL2 orbit, the Moon, Mars, and so onhas a gravitational force less than 1G.

Read more:
How Space Travel Tries to Kill You and Make You Ugly - WIRED

Read More...

New Study Finds That Wearing Contact Lenses Doesn’t Increase Risk of COVID-19 Infection – HealthDay Coronavirus Liveblog

Sunday, April 26th, 2020

Each week, HealthDay's Physician's Briefing division rounds up the most important COVID-19 developments in the medical field. See this week's edition below for April 20-April 24.

FDA Warns About Treating COVID-19 With Unproven Drugs

FRIDAY, April 24, 2020 (HealthDay News) -- Malaria drugs touted by some as potential "game changers" against COVID-19 are actually too dangerous for general use, the U.S. Food and Drug Administration warned Americans on Friday.

Read Full Article

Premature Posting of Remdesivir Findings Were 'Inconclusive'

FRIDAY, April 24, 2020 (HealthDay News) -- Inconclusive findings from a study investigating the antiviral drug remdesivir as a treatment for COVID-19 were posted to the World Health Organization website "prematurely," drug maker Gilead Sciences said Thursday.

Read Full Article

HTN, Obesity, Diabetes Common in U.S. COVID-19 Patients

FRIDAY, April 24, 2020 (HealthDay News) -- The most common comorbidities among patients hospitalized with COVID-19 in the New York City area are hypertension, obesity, and diabetes, according to a study published online April 22 in the Journal of the American Medical Association.

Read Full Article

Americans Report Concerns Over Their Mental Health During Pandemic

FRIDAY, April 24, 2020 (HealthDay News) -- Mental health concerns top economic worries during the COVID-19 pandemic, according to the results of a survey released by the University of Phoenix.

Read Full Article

COVID-19-Linked Changes Reported in Rheumatic Disease Patient Care

FRIDAY, April 24, 2020 (HealthDay News) -- Changes to health care have been reported among patients with rheumatic diseases during the COVID-19 pandemic, according to a study published online April 20 in ACR: Open Rheumatology.

Read Full Article

More Than One in Five Children in Home Confinement Report Depression

FRIDAY, April 24, 2020 (HealthDay News) -- During the COVID-19 outbreak in Hubei province in China, 22.6 percent of children in home confinement reported depressive symptoms, according to a research letter published online April 24 in JAMA Pediatrics.

Read Full Article

SARS-CoV-2 Stays in Respiratory Samples Longer in Severely Ill

FRIDAY, April 24, 2020 (HealthDay News) -- The median duration of severe acute respiratory syndrome coronavirus 2 RNA is significantly longer in the respiratory samples of patients with severe versus mild disease, according to a study published online April 21 in The BMJ.

Read Full Article

COVID-19 Outcomes Worse With Diabetes, Hyperglycemia

FRIDAY, April 24, 2020 (HealthDay News) -- Diabetes and/or uncontrolled hyperglycemia occur frequently among hospitalized patients with COVID-19 and are associated with worse outcomes, according to a study accepted for publication in the Journal of Diabetes Science and Technology.

Read Full Article

Survey Finds Anesthesiologists Prepared for COVID-19 Patients

FRIDAY, April 24, 2020 (HealthDay News) -- Anesthesiologists on the front lines of treating surgical COVID-19 patients in Turkey are generally knowledgeable about airway management, according to the results of a national survey published online April 6 in Surgical Infections.

Read Full Article

'Health Force' to Combat Pandemic Proposed by U.S. Senators

THURSDAY, April 23, 2020 (HealthDay News) -- A bill to create a "Health Force" to help combat the U.S. COVID-19 outbreak has been announced by two Democratic senators.

Read Full Article

White House Announces Payment Plan for Uninsured COVID-19 Patients

THURSDAY, April 23, 2020 (HealthDay News) -- A plan to begin paying hospitals and doctors who treat uninsured COVID-19 patients was announced by U.S. Health and Human Services Secretary Alex Azar on Wednesday.

Read Full Article

SARS-CoV-2 Can Spread Rapidly in Homeless Shelters

THURSDAY, April 23, 2020 (HealthDay News) -- Severe acute respiratory syndrome coronavirus 2 can spread rapidly in homeless shelters, according to two studies published in the April 22 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Read Full Article

CDC: More Chemical Exposures Reported in January to March 2020

THURSDAY, April 23, 2020 (HealthDay News) -- In January to March 2020, there were more chemical exposures reported to the National Poison Data System than in the corresponding months of 2019 and 2018, according to research published in the April 20 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Read Full Article

ACEIs/ARBs Not Linked to Severity or Mortality of COVID-19

THURSDAY, April 23, 2020 (HealthDay News) -- For patients with hypertension hospitalized with COVID-19 infections, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers are not associated with the severity or mortality of COVID-19, according to a brief report published online April 23 in JAMA Cardiology.

Read Full Article

Mild, No Symptoms Seen for Most Children With SARS-CoV-2 Infection

THURSDAY, April 23, 2020 (HealthDay News) -- Most children with severe acute respiratory syndrome coronavirus 2 infection have mild respiratory symptoms or are asymptomatic, according to a review published online April 22 in JAMA Pediatrics.

Read Full Article

AAD Establishes Registry for Skin Manifestations of COVID-19

THURSDAY, April 23, 2020 (HealthDay News) -- A registry has been created for reporting skin manifestations of COVID-19 following reports of patients presenting with skin conditions, including findings outlined in a letter to the editor published online March 26 in the Journal of the European Academy of Dermatology and Venereology.

Read Full Article

Lopinavir/Ritonavir, Umifenovir Ineffective for Mild COVID-19

THURSDAY, April 23, 2020 (HealthDay News) -- For patients hospitalized with mild/moderate COVID-19, lopinavir/ritonavir or umifenovir monotherapy offers little benefit, according to a study published online April 17 in Med.

Read Full Article

Rapid COVID-19 Test Can Produce False Negatives

WEDNESDAY, April 22, 2020 (HealthDay News) -- A widely used rapid COVID-19 test can produce false negatives if a certain solution is used to move or store patients' samples, the test's maker said.

Read Full Article

Expert Panel: There Are No Proven Drug Treatments for COVID-19

WEDNESDAY, April 22, 2020 (HealthDay News) -- There is no proven drug treatment for COVID-19 patients, according to a panel of experts convened by the U.S. National Institute of Allergy and Infectious Diseases.

Read Full Article

Hydroxychloroquine Seems Not to Cut Ventilator Use in COVID-19

WEDNESDAY, April 22, 2020 (HealthDay News) -- There is no evidence that use of hydroxychloroquine alone or with azithromycin reduces the risks for mechanical ventilation or death from any cause in patients hospitalized with COVID-19, according to a study that has not yet been peer reviewed and was posted online April 21 at medRxiv.org.

Read Full Article

ST-Segment Elevation Described in Patients With COVID-19

WEDNESDAY, April 22, 2020 (HealthDay News) -- For patients with COVID-19 who have ST-segment elevation, indicating potential acute myocardial infarction, there is considerable variability in presentation, and prognosis is poor, according to a letter to the editor published online April 17 in the New England Journal of Medicine.

Read Full Article

Obesity Ups Risk for COVID-19 Severity

WEDNESDAY, April 22, 2020 (HealthDay News) -- There is a high frequency of obesity among patients admitted to intensive care for severe acute respiratory syndrome coronavirus 2, according to a study published online April 9 in Obesity.

Read Full Article

Scoring System Helps Guide Surgical Care During COVID-19

WEDNESDAY, April 22, 2020 (HealthDay News) -- A scoring system for medically necessary time-sensitive procedures can facilitate decision making and triage in the setting of COVID-19, according to a study published online April 9 in the Journal of the American College of Surgeons.

Read Full Article

LA County COVID-19 Infections Far Exceed Number of Confirmed Cases

TUESDAY, April 21, 2020 (HealthDay News) -- An early analysis of antibody testing from Los Angeles County reveals a COVID-19 infection rate that is up to 55 times the number of confirmed COVID-19 cases.

Read Full Article

FDA Authorizes COVID-19 Test That Uses Samples Collected at Home

TUESDAY, April 21, 2020 (HealthDay News) -- The U.S. Food and Drug Administration has approved emergency use of the first COVID-19 test that enables patients to take samples at home.

Read Full Article

Mental Health Consequences of COVID-19 Pandemic Explored

TUESDAY, April 21, 2020 (HealthDay News) -- A new position paper, published online April 15 in The Lancet Psychiatry, highlights the mental health consequences of COVID-19 management.

Read Full Article

COVID-19 Tied to Unique Nasal Symptoms

TUESDAY, April 21, 2020 (HealthDay News) -- COVID-19 is not associated with the symptoms typically associated with a viral cold or allergies, such as nasal blockage or mucus production, according to a review published online April 10 in Laryngoscope Investigative Otolaryngology.

Read Full Article

Expanding Symptom Screening Criteria Can Up COVID-19 Detection

TUESDAY, April 21, 2020 (HealthDay News) -- Expanding COVID-19 symptom screening criteria to include myalgias and chills could identify more health care personnel with the illness, according to a research letter published online April 17 in the Journal of the American Medical Association.

Read Full Article

176,190 U.S. Children Estimated to Have SARS-CoV-2 by April 6, 2020

TUESDAY, April 21, 2020 (HealthDay News) -- About 176,190 children nationwide were estimated to be infected with severe acute respiratory syndrome coronavirus 2 by April 6, 2020, according to a study published online April 16 in the Journal of Public Health Management & Practice.

Read Full Article

Coinfection With SARS-CoV-2, Other Respiratory Pathogens ID'd

TUESDAY, April 21, 2020 (HealthDay News) -- About 20 percent of specimens positive for severe acute respiratory syndrome coronavirus 2 infection are positive for other respiratory pathogens, according to a research letter published online April 15 in the Journal of the American Medical Association.

Read Full Article

Cardiac Cath Lab STEMI Activations Drop During Pandemic

TUESDAY, April 21, 2020 (HealthDay News) -- During the COVID-19 pandemic, there has been a 38 percent reduction in U.S. cardiac catheterization laboratory ST-segment elevation myocardial infarction activations, according to a research letter published online April 10 in the Journal of the American College of Cariology.

Read Full Article

Lab Protocol Failures Led to Ineffective COVID-19 Tests From CDC

MONDAY, April 20, 2020 (HealthDay News) -- The first COVID-19 tests in the United States were ineffective due to poor laboratory practices at the U.S. Centers for Disease Control and Prevention, the U.S. Food and Drug Administration said.

Read Full Article

Public Health Measures Cut COVID-19 Transmission in Hong Kong

MONDAY, April 20, 2020 (HealthDay News) -- Public health measures implemented to suppress local transmission of COVID-19 in Hong Kong were associated with reduced transmission of COVID-19 and influenza, according to a study published online April 17 in The Lancet Public Health.

Read Full Article

See the original post here:
New Study Finds That Wearing Contact Lenses Doesn't Increase Risk of COVID-19 Infection - HealthDay Coronavirus Liveblog

Read More...

Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome – Rheumatology Advisor

Saturday, April 25th, 2020

Peripheral neuropathy is a common complication of primary Sjgren syndrome and may be associated with a diminished health-related quality of life (HR-QoL), according to research results published in Rheumatology International.

Researchers sought to compare HR-QoL outcomes in patients with primary Sjgren syndrome, both with and without peripheral neuropathy. They also aimed to examine the associations between the neurologic complications and components of HR-QoL outcomes using the 36-item Short Form Health Survey (SF-36). Overall, 50 adult patients with primary Sjgren syndrome (median age, 57.5 years; 96% women) were included in the study.

Of the total cohort, 80% (n=40) reported subjective symptoms, including paresthesia or other symptoms that were suggestive of neuropathic pain on a periodic or permanently present basis. In total, 46% (n=23) of patients met the criteria for a diagnosis of peripheral neuropathy (PNS+); the remaining patients were referred to as PNS-.

Researchers indicated the most common peripheral nervous system manifestation to be sensorimotor neuropathy, which was present in 47% of patients who were PNS+. Mononeuropathy was present in 26%, pure axonal sensory neuropathy, axonal motor neuropathy, and small fiber neuropathy were each present in 4.3%, and cranial nerve involvement was present in 17.4% of patients who were PNS+; 1 patient experienced both cranial and sensorimotor neuropathy. Among 35% of patients who were PNS+, neurologic symptoms preceded patients diagnosis of primary Sjgren syndrome.

Investigators studied data from both groups of patients in terms of clinical characteristics and laboratory testing results, and observed similarity in age, disease duration, time from diagnosis, and time of symptom onset. Clinical manifestations, including parotid enlargement, respiratory tract involvement, lymphadenopathy, and hypocomplementemia were significantly more prevalent among patients who were PNS+ vs those who were PNS- (74% vs 44%; 65% vs 37%; 61% vs 19%; and 26% vs 7%, respectively). In addition, patients in the PNS+ vs PNS- group were statistically significantly more likely to frequently use cyclophosphamide because of extraglandular manifestations (17% vs 0%, respectively).

Both groups were also compared based on the results of the visual analog scale (VAS)-pain scale, SF-36, and an interview regarding pain type. Among patients who were PNS+ vs PNS-, median VAS-pain was 3 vs 0, respectively (range, 0-7; P =.229). Neuropathic type pain was often observed across both subgroups but was predominantly among patients who were PNS+ compared with those who were PNS- (70% vs 41%).

Across the 5 domains of the SF-36, patients who were PNS+ vs PNS- had significantly lower results in terms of physical and emotional roles, vitality, bodily pain, and general health (P .05).

Study limitations included potential referral bias in patient selection, researchers inability to conduct neurophysiologic testing in individuals suspected of pure small-fiber neuropathy, and a lack of unambiguous differentiation between Sjgren syndrome-related neuropathy and other forms of neuropathy.

Our study showed that peripheral nervous involvement is frequent in [patients with primary Sjgren syndrome] and it is correlated with worse HR-QoL, the researchers concluded. To get the complete picture of [patients with Sjgren syndrome], a holistic approach starting with a comprehensive assessment of disease activityis needed.

Reference

Jasklska M, Chylinska M, Masiak A, et al. Peripheral neuropathy and health-related quality of life in patients with primary Sjgrens syndrome: A preliminary report [published online March 14, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04543-2

Go here to see the original:
Peripheral Neuropathy Is Common, Associated With Diminished Health-Related Quality of Life in Sjgren Syndrome - Rheumatology Advisor

Read More...

Elias Theodorou: Fighting style was affected by bilateral neuropathy before receiving cannabis TUE – MMA Fighting

Saturday, April 25th, 2020

Dont be surprised if the next time you see Elias Theodorou compete, hes a different fighter than he was in the UFC.

The Spartan parted ways with the promotion last May coming off of a loss to Derek Brunson at UFC Ottawa, despite that being his first loss in four fights and his overall UFC record standing at 8-3. In those 11 appearances, Theodorou only logged two finishes his last in March 2015 and that lack of an exclamation point on his performances may have contributed to his departure.

In February, Theodorou became the first MMA fighter to receive a therapeutic use exemption for medical cannabis, which was granted to him by the British Columbia Athletic Commission. The 31-year-old Canadian has long been an advocate for the use of cannabis as a medical treatment and he has used it to help him to deal with bilateral neuropathy pain that affects his arms and hands.

Theodorous condition influenced his approach to his UFC fights, with cannabis strictly prohibited in competition under USADA guidelines, and he spoke about how much being able to self-medicate will benefit him in the future.

I have bilateral neuropathy, so nerve damage of my upper extremities, Theodorou said on Mondays episode of The A-Side live chat. My actual hands are where the issues are and a lot of my fighting style over the last couple of days was actually taking that into account and moving around it.

Now, being able to medicate and not having those flare-ups that I normally have, because again putting your body through not only training and the condition that I already have and also the weight cut itself inhibits my ability to compete at a level playing field.

Theodorou said that medical cannabis is useful both for calming his nerves and dealing with the pain management of a competitive fighting career. Athletes in pro sports are often prescribed opioids, pain killers, and other drugs to address their maladies, and Theodorou believes adding cannabis to that list is a matter of medical equality.

While he may have utilized different tactics inside the octagon with his bilateral neuropathy unchecked, Theodorou isnt blaming his three UFC losses on not being allowed to medicate with cannabis.

I fought some really tough guys and I won more than Ive lost many times over, Theodorou said. The ones that I lost I wouldnt chalk it up to anything in regards to inability to medicate. Each individual fight is each individual situation, so Id never use an excuse, the better man won I would say. But again, the only people that Ive ever lost to were top-10 in the world at the time, and one of those persons happened to be Thiago Santos. Even in that situation I was able to take everything he threw at me and never quit.

One of the things I was able to learn from it is that even as a professional fighter, fight or flight is kind of still ingrained in us. Even when push comes to shove, I can still fight under the worst situations and in the bloodiest of wars.

In celebration of 4/20 the April 20 celebration widely recognized by cannabis culture Theodorou was hoping to fight in April in British Columbia, where he was granted his exemption, though a bout was never finalized. Wherever he competes next, Theodorou is optimistic that his TUE will carry over to other jurisdictions.

Because of the way that the whole system works in regards to the commissions, now that I got a therapeutic use exemption in one jurisdiction, most if not all should validate my exemption because of the way it all works out, Theodorou said. The case in point would be if someone got suspended for steroid use and they were suspended for a year in, lets say, New York, California wouldnt allow them to get registered until their suspension is over.

Well, the same thing happens in positive rulings. Thats the case in regards to my therapeutic use exemption. Theres already preliminary conversations with other commissions that, again, once I get a fight booked in that area theyll most likely validate my therapeutic use exemption. Obviously, it was a lot of hard work and it was able to [happen] because of me arguing my fundamental Canadian right to medicate as prescribed by my doctor in B.C., but now because of that ruling Im able to take that precedent and run with it not only in B.C. but everywhere else I fight.

Theodorou has already fought once since leaving the UFC, picking up a third-round finish against fellow big show vet Hernani Perpetuo at a show in Windsor, Ontario, last December. According to Theodorou, he was not tested for cannabis ahead of that fight and being able to self-medicate made a world of difference.

In reality, that was the first fight I was able to medicate as prescribed by my doctor and obviously, the results show for themselves, Theodorou said. Competing at the highest level at the way I was because of the strict testing, in many ways I was competing at a disadvantage compared to other athletes that can medicate as prescribed by their doctors. So now with the TUE and other avenues to compete on a competitive playing field, Im excited to keep that win streak going and smash the next person that stands in front of me.

See the rest here:
Elias Theodorou: Fighting style was affected by bilateral neuropathy before receiving cannabis TUE - MMA Fighting

Read More...

COVID-19: Responding to the business impacts of Neuropathic Pain Management Revenue Growth Predicted by 2019-2028 – Jewish Life News

Saturday, April 25th, 2020

Analysis Report on Neuropathic Pain Management Market

A report on global Neuropathic Pain Management market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Neuropathic Pain Management Market.

Request Sample Report @https://www.mrrse.com/sample/8659?source=atm

Some key points of Neuropathic Pain Management Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Neuropathic Pain Management Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Neuropathic Pain Management Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Neuropathic Pain Management market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Neuropathic Pain Management market is analyzed and depicted in the report.

The global Neuropathic Pain Management market segment by manufacturers include

Segmented as Follows:

This report covers the global neuropathic pain management market performance in terms of revenue contribution from various segments. The report begins with an overview of the neuropathic pain management and its definitions. The market viewpoints section underlines macro-economic factors influencing the growth of the neuropathic pain management market along with detailing its opportunity analysis.

The global neuropathic pain management market is segmented based on drug class, indication, distribution channel and region. On the basis of drug class, the market has been segmented as tricyclic anti-depressants anticonvulsants, serotoninnorepinephrine reuptake inhibitor, capsaicin cream, local anaesthesia, opioids, steroids and others.

On the basis of indication, the market is segmented as diabetic neuropathy, trigeminal neuralgia, post-herpetic neuralgia, chemotherapy-induced peripheral neuropathy and others.

On the basis of distribution channel, the market is segmented as hospital pharmacies, retail pharmacies and online pharmacies.

A detailed analysis has been provided for each region in terms of market size, BPS analysis, Y-o-Y growth rate, absolute $ opportunity, and market attractive index. The regional market dynamics provide the key growth driver, restraints, and trends pertaining to each region. The forecast of the neuropathic pain management market by country, drug class, indication, distribution channel are represented in the tabular form for each region. This section also helps to understand the opportunity of the neuropathic pain management market in major countries by each segment.

In the next section of the report, the Competitive Landscape is included to provide report audiences with a dashboard view and to access the key differentiators among the competitor firms. This section is primarily designed to provide clients with an objective and detailed comparative assessment of product offerings and strategies of key providers specific to the market segments. Detailed profiles of players in the neuropathic pain management market are also provided in the report, which highlights company description, product/segment overview, SWOT analysis, financial information, key developments related to market and strategic overview.

The next section of the report highlights the market outlook for 20182026 and sets the forecast within the context of the neuropathic pain management market by region. The key regions assessed in this report include North America, Latin America, Europe, Asia Pacific and MEA. A detailed analysis has been provided for each region in terms of market size, Y-o-Y growth rate, absolute $ opportunity, and market attractive index.

The above sections by drug class, indication, distribution channel evaluate the historic market analysis for the period of 20132017 and growth prospects of the neuropathic pain management market for the period 20182026. We have considered 2016 as the base year and provided data for the forecast period.

The final section of report represents the global scenario for the neuropathic pain management market along with Y-o-Y growth and market forecast till 2026. This section also evaluates the global market opportunity over the forecast period and also the absolute dollar opportunity for each year. This section will help to understand the overall market growth of the neuropathic pain management market and the opportunity analysis for each year over the forecast period.

Bottom-up approach is used to validate the total market size obtained. The forecast presented in the report provides total revenue of the neuropathic pain management market over 20182026. While forecasting the market size, we have considered the impact of several factors such product approvals for neuropathic pain management, R&D investment by major players, pipeline analysis, penetration of products in different distribution channel, generic penetration across all regions, etc. However, quantifying the market across the aforementioned segments and regions is more a matter of quantifying expectations and identifying opportunities rather than rationalizing them after the forecast has been completed. In addition, we have taken into consideration the year-on-year growth to understand the predictability of the market and to identify the right growth opportunities in the global market.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/8659?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Neuropathic Pain Management economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/8659?source=atm

Benefits of Purchasing Neuropathic Pain Management Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read the original post:
COVID-19: Responding to the business impacts of Neuropathic Pain Management Revenue Growth Predicted by 2019-2028 - Jewish Life News

Read More...

Nerve Pain: Know Everything About it – Living Gossip

Saturday, April 25th, 2020

Pain is inevitable but can be managed This often results in a way of numbness, or lack of sensation. However, in some cases when this technique is injured, individuals experience pain within the affected region. Neuropathic pain doesnt start abruptly or resolve quickly; its a chronic condition that results in persistent pain symptoms. for several patients, the intensity of their symptoms can wax and wane throughout the day. Although neuropathic pain is assumed to be related to peripheral nerve problems, like neuropathy caused by diabetes or spinal stenosis, injuries to the brain or medulla spinalis also can cause chronic neuropathic pain.

Neuropathic pain is often contrasted to nociceptive pain, which is that the sort of pain which occurs when someone experiences an acute injury, like smashing a finger with a hammer or stubbing a toe when walking barefoot. this sort of pain is usually short-lived and typically quite aware of common pain medications in contrast to neuropathic pain.

Tramadol is a medication that is available online and can be used to relieve pain.

Tramadol without prescription in USA is available on the web if you want to check it out

Anything that results in loss of function within the sensory systema nervosum can cause neuropathic pain. As such, nerve problems from carpal tunnel syndrome or similar conditions can trigger neuropathic pain. Trauma, causing nerve injury, can cause neuropathic pain. Other conditions that may predispose patients to develop neuropathic pain include diabetes, vitamin deficiencies, cancer, HIV, stroke, MS, shingles, and cancer treatments.

Neuropathic pain may be a painful condition thats usually chronic. Its usually caused by chronic, progressive nerve disease, and it also can occur because of the results of injury or infection.

If youve got chronic neuropathic pain, it can flare up at any time without a clear pain-inducing event or factor. Acute neuropathic pain, while uncommon, can occur.

Typically, non-neuropathic pain (nociceptive pain) is thanks to an injury or illness. for instance, if you drop an important book on your foot, your system a Nervo sum sends signals of pain immediately after the book hits.

With neuropathic pain, the pain isnt typically triggered by an occasion or injury.

People with this painful condition may experience shooting, burning pain. The pain could also be constant or may occur intermittently. a sense of numbness or a loss of sensation is common, too.

Neuropathic pain tends to urge worse over time. About 1 in 3 Americans experience chronic pain. Of those, 1 in 5 experience neuropathic pain.A 2014 study estimated that as many as 10 percents of USA citizens experience some sort of neuropathic pain.

Understanding the possible causes can assist you to find better treatments and ways to stop the pain from getting worse over time.Nerve Pain & Nociceptive PainYou can have nerve pain and nociceptive pain together. Both pain types are often caused by an equivalent condition.

Nerve pain is a smaller amount likely than nociceptive pain to be helped by traditional painkillers like paracetamol, anti-inflammatories, and codeine. However, other sorts of medicines often work well to ease the pain. Nerve pain is usually eased by anti-depressant or anti-epileptic medicines. Please ask your doctor for more advice.

There are pain medication like Tramadol COD available from many online pharmacies and can be bought easily

View original post here:
Nerve Pain: Know Everything About it - Living Gossip

Read More...

Mar 4 | Spine Imaging and Intervention in Palm Springs | Palm Desert – Patch.com

Saturday, April 25th, 2020

Multiple disease categories will be covered during this 2 1/2-day course, which will focus on diagnosis, treatment, image-guided diagnostic and therapeutic procedures, indications for surgery, and evaluation of the post-operative patient.

At the conclusion of this activity, participants should be able to:

-Identify key imaging findings in spine trauma and other spine emergencies

-Understand imaging techniques and observations in peripheral neuropathy, vascular diseases of the spine and spinal cord lesions, spine infections and spine tumors.

-Describe degenerative changes in the spine and the radiologists role in diagnosis of spine conditions and pain management.

-Understand the basics of Regenerative Medicine

-Be familiar with advanced imaging techniques of the spine including diffusion imaging and fMRI.

-Know what the spine surgeon is looking for in the preoperative and postoperative imaging studies.

URLs:Website:https://go.evvnt.com/643445-0?...Tickets:https://go.evvnt.com/643445-1?...

Date and Time: On Thursday March 04, 2021 at 7:00 am (ends Saturday March 06, 2021 at 10:00 am)

Category: Conferences | Science, Health and Medicine | CME (Continuing Medical Education)

Prices:Practicing Physician/Industry: USD 1295.00,Military/Retired/Scientist/VA : USD 1195.00,Resident/Fellow/Technologist/PA/Nurse: USD 995.00

Speakers: Blake Johnson, MD, John Feller, MD, Adam Flanders, MD, Wende Gibbs, MD, David Polly, MD, Phillip Tirman, MD

Continue reading here:
Mar 4 | Spine Imaging and Intervention in Palm Springs | Palm Desert - Patch.com

Read More...

My eyesight is weak, but my vision is strong – Pursuit

Saturday, April 25th, 2020

When I was born, my parents were super surprised. They had never seen a child with albinism, and they could not understand what had happened. But they always loved and supported me.

I grew up in a city in the Indian state of Haryana, near Delhi. There were so many social issues because of my different appearance, and I didnt get accepted in society.

I have a vision impairment and my parents didnt know how to help. They tried their best, but they felt sad because whenever we went to doctors, they said, We have no solution for that.

My academic life has been very challenging because of my vision impairment. But a strong determination, my parents love and educators support helped me to overcome every challenge.

I earned an Honours degree in Chemistry from one of the best institutions in India, St Stephens College, which belongs to Delhi University. I followed this with a Masters in Chemistry from the Indian Institute of Technology Kanpur (IIT-Kanpur).

Read more

I received a number of awards and honours for academic excellence during my studies. These included the Sangeeta Predham Memorial Medal for the most outstanding graduating Master of Science student, and the Dr Elizabeth and Dr Verkey Cherian Award for Best Project at the summer undergraduate research and graduate excellence program, to name few examples.

I wanted to pursue my love for chemistry, so I moved to the University of Melbourne to do a PhD with Dr Lars Goerigk. My studies here in Melbourne are supported by the Melbourne International Engagement award through the Melbourne India Postgraduate Program.

The broad aim of my PhD is to assess the applicability of density-functional theory (DFT) approximations. DFT has become the most important electronic-structure calculation tool both in the computational/theoretical chemistry as well as in the experimental community.

The latter use it to validate their findings and predict experimentally challenging and unexplored questions. As such, DFT plays an important role in the synthesis of new molecules and materials. Density-functional theory (DFT) approximations are readily available in many quantum chemistry programs.

Many high-impact studies rely on DFT, but they often ignore that the field is more complex than it seems. Despite being popular and easily available, people have to rely on approximations to the unknown true model.

A large number of these approximations have been developed, each with their own advantages and disadvantages. Therefore, the field is full of misconceptions, suffers from confusion in the user community, low-acceptance rate of newly developed methods and, ultimately, the high risk of providing the wrong answer to a research question.

Read more

In the first project of my PhD, we addressed some of these risks and misconceptions. This work is one of the largest and most thorough DFT benchmarking studies in existence, and allowed us to clean up the ever-growing zoo of DFT methods. We identified a handful of computational strategies that distinguish themselves in terms of their accuracy and reliability.

This study identifies the most accurate density functionals, and so impacts the general chemistry community beyond my own specialised field. Our work was very well received by reviewers, published as a front-cover article in one of the leading journals in my field, Physical Chemistry Chemical Physics (PCCP), and made it into the 2018 PCCP HOT article themed collection.

It immediately went to the top 25 per cent of all research outputs scored by Altmetrics (which tracks the attention that research is getting) and was acknowledged with two poster prizes at the fifth Royal Society of Chemistry Twitter Poster Conference, which reached more than two million viewers.

We also presented a new analysis of the openly available data published in Swart and co-workers famous annual DFT poll (an online poll that asks the DFT community to identify their preferences among the many approximations that are available.)

We demonstrated that there is a communication gap between the DFT user and developer communities. We showed that despite considerable methodological advances in the field, the perception of some parts of the user community regarding their favourite approaches has changed little since 2010.

Now that we have identified the most reliable and fast DFT approximations, we are using these to gain computational insights into various chemical systems that have proven difficult to explore experimentally. These results are providing an insightful understanding and useful guidance for future synthesis of various chemical systems.

Read more

On International Day of Persons with Disabilities last December, I had the great honour to receive the National Award for Empowerment of Persons with Disabilities. This award was in the category of Role Model in a presidential ceremony in India.

This award is for all those who have supported me, including my friends, supervisor Dr Lars Goerigk, parents Sunita Mehta and Ved Prakash Mehta, and brother Sourabh Mehta.

This moment is to tell the world Yes, I look different, my eyesight is weak, but my vision is strong.

- As told to Dr Daryl Holland.

Banner: Getty Images

See the original post:
My eyesight is weak, but my vision is strong - Pursuit

Read More...

Vision research and eye health in time of COVID-19 – Mirage News

Saturday, April 25th, 2020

Social distancing is not stopping CERA scientists from continuing critical research to discover better treatments to prevent vision loss and restore sight.

Managing Director Professor Keith Martin says most of our scientists are now continuing their research remotely and coming up with novel solutions to keep their investigations on track at new locations.

Even though we are not all together in the clinic or lab, we are still working towards our common goal of discovering better ways to diagnose, prevent and treat vision loss and, ultimately, find cures that will restore lost sight, he says.

However, our team at the Clinical Trials Research Centre, which has recently relocated back to the main hospital building at the Royal Victorian Eye and Ear Hospital in East Melbourne, is working on-site providing continuity of care for trial participants.

The Clinical Trials Research Centre is continuing to treat patients with conditions including diabetic macular oedema, wet age-related macular degeneration, uveitis, corneal disease and glaucoma, says Professor Martin.

We have temporarily stopped recruiting patients for new clinical trials but are providing important continuity for patients who are receiving critical sight-saving treatment as part of existing trials.

Face-to-face visits in our Macular Research Unit have been deferred for now.

Trial coordinators from our macular team are in touch with their trial participants about upcoming appointments and are available to answer any queries patients have over the phone.

However, the teams critical work to find better treatments, and a cure, for AMD is continuing.

Face-to-face visits for macular research have been deferred.

Our macular researchers are now working from home, analysing images and data collected from patient visits to gather more evidence about what causes AMD.

Other research teams analysing results from laboratory-based experiments, developing algorithms for artificial intelligence diagnostic tools, creating new tele-medicine tools to monitor eye health, or building and testing innovative imaging devices.

Professor Martin says that even though routines have changed because of COVID-19 social distancing rules, older people and those with conditions like diabetes should continue to keep an eye on their vision at home.

The COVID-19 pandemic is a difficult time for all of us, but it is still important to keep looking after your eyes, he says.

Although many ophthalmologists and optometrists have deferred routine appointments, visits for sight-saving treatments like injections for age-related macular degeneration or diabetic eye diseases are considered essential.

Anyone who experiences a sudden change in their vision or is concerned about their sight should contact their regular optometrist or ophthalmologist.

Professor Martin, a glaucoma specialist, and some of CERAs other eye research experts offered the following eye health tips during the COVID-19 crisis.

If you have glaucoma, your routine appointment with your eye specialist may have been deferred but you shouldnt be concerned about this, says Professor Martin.

Its very important that they keep using their regular eye drops as prescribed by your ophthalmologist until your next appointment. You dont need to worry if you run out of drops before your next appointment as your pharmacist can provide up to one months supply of your regular prescription.

If you are receiving regular eye injections for AMD, it is important that you attend these as determined by your ophthalmologist if you can, says Professor Robyn Guymer AM, ophthalmologist and Head of CERAs Macular Research Unit.

These appointments are considered essential medical treatments and you can take along a support person if you need to.

Eye clinics are adhering to physical distancing measures, minimising time spent in the waiting room and using personal protective equipment to safeguard patients during their clinic visits.

While you are at home staying safe from COVID-19 you should continue to monitor your eye health.

You should still look at your Amsler Grid once a week and if there is distortion or blur and its persistent, contact your regular optometrist or ophthalmologist.

Associate Professor Peter van Wijngaarden, CERA Deputy Director and Clinical Director of the KeepSight Program, says regular eye checks are important for people with diabetes.

During the COVID-19 pandemic, most routine eye checks for people with diabetes can be safely deferred, he says.

However, if you have existing eye damage or disease, or usually have check-ups more than every six months, you should phone your eye care provider to clarify when you should see them again.

If you are having laser treatments or injections you should contact your ophthalmologist to discuss your treatment, as in some cases interruption of treatment can lead to vision loss.

And anyone with diabetes who has sudden changes in vision should treat it as an emergency and contact their optometrist or ophthalmologist for advice.

Original post:
Vision research and eye health in time of COVID-19 - Mirage News

Read More...

Eye care treatment centres set up across Scotland after 3m investment – Aberdeen Evening Express

Saturday, April 25th, 2020

New centres have been set up to help Scots who suffer emergency eye problems during the coronavirus pandemic.

Health Secretary Jeane Freeman has announced 3 million of Scottish Government cash towards the creation of more than 50 emergency eye care treatment centres.

These are being set up in all health board areas, while hubs in NHS Grampian and NHS Forth Valley will also benefit from new technology.

Live video and audio feeds between the centres and consultants in hospitals are being used to allow more patients to be immediately diagnosed and treated.

Patients, who will have an initial telephone consultation, will be referred to optometrists if needed.

Ms Freeman said: While services have changed dramatically over the last few weeks, my message is clear if you are worried about your health in any way, please get in touch with your GP.

The same applies to your vision if you have experienced any problems with your sight, please contact your local high street optician as soon as possible.

She thanked health boards and eye care specialists for the excellent collaboration in establishing, at pace, more than 50 emergency eye care treatment centres across Scotland to manage patients without Covid-19 symptoms who need an emergency face-to-face consultation.

The Health Secretary added: I am pleased to see some NHS boards are also using innovative new tele-ophthalmology technology.

This means that more patients can be immediately diagnosed and treated in a community setting while gaining an expert opinion from the secondary care ophthalmology team.

Here is the original post:
Eye care treatment centres set up across Scotland after 3m investment - Aberdeen Evening Express

Read More...

Peterborough residents urged to keep an eye on vision and hearing problems during lockdown – Peterborough Telegraph

Saturday, April 25th, 2020

While Specsavers in Peterborough are closed for all routine eye and hearing tests at the moment, they are still open to provide essential care and to support local key workers.

Customers are being encouraged to contact their local store if they need urgent support with a visual problem, or if they have issues with their glasses, contact lenses or hearing aids.

If anyone is required to attend the store, they will be asked to do so and key workers will be prioritised. Any face to face contact will be minimal and will be handled in line with current Government guidelines.

Recently, the team were able to assist a vulnerable customer who was unable to drop off his hearing aids in store for a repair, as he was self-isolating. A team member offered to take a look at the customers hearing aids at his home free of charge, carrying out the necessary clean and repairs on the equipment all whilst wearing full PPE.

After cleaning the debris out of the customers hearing aids, the team member even returned for a second visit later on to drop off some spare drying capsules to the customer who had run out.

Chintu Patel, store director at Specsavers in Peterborough, said: We want the local community to know that, while we are closed for routine appointments at the present time, we are still very much here to support people with their essential eye and hearing care needs, and to make sure they can see and hear healthily whilst staying at home.

Eye and ear health remains really important, and providing the local community and vulnerable people with access to professional optical and audiology services whilst lockdown continues, is why were determined to stay operational. Please do give us a call if you need assistance because were more than happy to help.

Specsavers teams are classed as key workers to provide urgent and essential eye care to those who need it. This includes supporting other key workers who couldnt function without their help and people who would come to harm without their health expertise, especially where the usual hospital services and NHS facilities are being prioritised for the fight against COVID-19.

Customers can also visit Facebook to have any questions on their sight and hearing answered by expert optometrists and audiologists,

here: https://www.facebook.com/groups/SpecsaversAskTheExpert/?fref=nf.

See the rest here:
Peterborough residents urged to keep an eye on vision and hearing problems during lockdown - Peterborough Telegraph

Read More...

Focus on Eyes: Cocaine, meth, other vices affect eyes more than you know – Florida Today

Saturday, April 25th, 2020

Dr. Frederick Ho, Special to FLORIDA TODAY Published 6:29 a.m. ET April 21, 2020

Smoking, binge drinking and illicit drug use can lead to serious eye problems.(Photo: Getty images)

An unhealthy lifestyle translates into many health problems.

Smoking, binge drinking and illicit drug use are known to cause cancer, diabetes, heart disease, lung damage, stroke and death. They can also lead to serious eye problems.

Cigarette smoking remains a major health issue despite of years of health warnings and public awareness campaigns.

Smoking has been linked to early development of macular degeneration and cataracts.

Dr. Frederick Ho(Photo: FLORIDA TODAY FILE)

Compared to non-smokers, people who smoke a pack or more per day are two-to-three times more likely to develop macular degeneration an aging condition in the retina, affecting the central vision.

The inhaled substances in cigarette smoke constrict the blood vessels and promote blood clot formation in the retina and optic nerves.

Partial to almost complete blindness happens when there is thrombosis, or blood clot, in the central retinal artery, which is the main artery that supplies blood, oxygen and nutrients to the retina.

Smoking increases the risk of ischemia, or stroke, in the optic nerve, which transmits the images from the eye to the brain, resulting significant permanent visual loss.

About one-in-six adult Americans binge drinks about four times a month, consuming about eight drinks each time.

There is a well-established linkage between Type 2 diabetes and excessive alcohol consumption.

The most serious ocular complications of diabetes is diabetic retinopathy. The diabetes-damaged retina develops hemorrhages and swelling, resulting in visual loss.

Alcohol abuse increases the incidence of early onset of cataracts and macular degeneration.

More: Focus on Eyes: Chinese ophthalmologist warned about COVID-19 outbreak

More: Focus on Eyes: Celebrating America's first black ophthalmologist

More: Focus on Eyes: What does it mean to have 20/20 vision

Methanol, or wood alcohol, in contaminated moonshine damages the optic nerve, and if untreated,the person will suffer partial to total blindness.

Ocular trauma with visual loss is too often seen with alcohol intoxication.

Illegal substance abuse is at the extreme end of vices.

It is estimated about 10 percent of adults use illegal drugs.

There are many deleterious effects to the eyes.

Intranasal cocaine use is particularly damaging and potentially leading to acute attack of angle closure glaucoma, retinal hemorrhages and optic nerve damage.

Smoking crack cocaine is associated with infection and diminished blood flow to the retina.

Methamphetamine use is known to cause infection in the cornea which is the transparent tissue in front of the eye.

Retinal inflammation is also seen in methamphetamine use.

Intravenous drug abuse introduces infection to the eyes and particles clotting the blood vessels in the retina and the optic nerve.

Many people assume their vices will get their eyes red and eyelids droopy.

In fact, they can suffer from many sight threatening complications.

Hopefully, this will motivatethem to give up their vices and adopt healthy habits.

Dr. Frederick Ho,the medical director of Atlantic Eye MD and Atlantic Surgery and Laser Center, is a board certified ophthalmologist. Atlantic Eye MDis located at 8040 N. Wickham Road in Melbourne. To make an appointment please call (321) 757-7272. To learn more visit AtlanticEyeMD.com.

Read or Share this story: https://www.floridatoday.com/story/life/wellness/2020/04/21/focus-eyes-cocaine-meth-other-vices-affect-eyes-more-than-you-know/5164034002/

Read the rest here:
Focus on Eyes: Cocaine, meth, other vices affect eyes more than you know - Florida Today

Read More...

Glaucoma can be successfully treated with gene therapy – Telangana Today

Saturday, April 25th, 2020

London:A common eye condition, glaucoma, could be successfully treated with a single injection using gene therapy, which would improve treatment options, effectiveness and quality of life for many patients, say researchers.

Glaucoma affects over 64 million people worldwide and is a leading cause of irreversible blindness. It is usually caused by fluid building up in the front part of the eye, which increases pressure inside the eye and progressively damages the nerves responsible for sight.

Current treatments include either eye drops, laser or surgery, all of which have limitations and disadvantages.

At present, there is no cure for glaucoma, which can lead to loss of vision if the disease is not diagnosed and treated early, said study researcher Dr Colin Chu from the University of Bristol in the UK.

For the findings, published in the journal Molecular Therapy, the research team tested a new approach that could provide additional treatment options and benefits.

The researchers designed a gene therapy and demonstrated proof of concept using experimental mouse models of glaucoma and human donor tissue.

The treatment targeted part of the eye called the ciliary body, which produces the fluid that maintains pressure within the eye.

Using the latest gene-editing technology called CRISPR, a gene called Aquaporin 1 in the ciliary body was inactivated leading to reduced eye pressure.

We hope to advance towards clinical trials for this new treatment in the near future. If its successful it could allow a long-term treatment of glaucoma with a single eye injection, which would improve the quality of life for many patients whilst saving the NHS time and money, Chu said

The researchers are currently in discussion with industry partners to support further laboratory work and rapidly progress this new treatment option towards clinical trials.

Read this article:
Glaucoma can be successfully treated with gene therapy - Telangana Today

Read More...

Michelle Cretella is Back – Along With Her Sophistry – The Slowly Boiled Frog

Saturday, April 25th, 2020

If Dr. Michelle Cretella disagrees with the science then she should publish. She never has and she never will because she can't.

The pediatrician that Murphee is referring to is Michelle Cretella, executive director of American College of Pediatricians (ACPeds). Southern Poverty Law Center deems ACPeds to be an anti-LGBTQ hate group as well.

Before we wander into the text it is important to understand that Michelle Cretella's point of view is not as a physician. Not at all. Cretella is a Catholic extremist. Cretella conforms to Vatican doctrine, no matter how idiotic that might be and, according to the Vatican, transgender people do not really exist.

As for Murphee's title, insanity is substituting religious dogma for medical science. The dogma emanates from celibate prelates who are theologians and catechists with no training or experience in medical science.

And we begin

Junk scientist! they shout. Hater!

All lies.

She is, however, a formidable foe of the transgender activist agenda and in its view, a villain to be destroyed.

Furthermore, Michelle Cretella is not a foe of mythical activists. Rather, Cretella is a foe of gender-affirming care which is the clinical standard of care according to her former peer group, the American Academy of Pediatrics.

Michelle Cretella is in a battle of her own making. The two sides are religious dogma vs. medical science. But it is not that simple. Cretella is intellectually dishonest. She is promoting faith-based Catholic doctrine as if it were evidence-based science. That constitutes the big lie.

Speaking of bullshit

I have no quarrel with what Mr. Murphee calls biblical truths other than the fact that scripture might have been accepted as truth when it was written but is not scientifically truthful today. Even then, Cretella's religious beliefs are hers to hold. Yet, she is not entitled to promote religious beliefs as science.

Cretella is claiming, essentially, that a sinister conspiracy to intentionally damage children exists. Doctors and educators and the media and secular people and They are allin on it.

If she believes that she has a better treatment plan for acute pediatric gender dysphoria then she should do what experts in this area routinely do which is to publish findings to reputable academic journals. She never has. She cannot.

As for surgery (which Murphee presents for shock value), about 30% of transgender people have gender-affirming surgery. At least a year of behavioral health therapy is required for a patient to qualify. Is 30% many?

No transgender person gives a flying fuck whether or not Murphee or Cretella approve of them. Transgender people are entitled to common courtesy. In polite society, we address people as they choose to be addressed. Trans people expect to be addressed according to their gender.

Misgendering trans people particularly trans kids does violence to them. It is gratuitously cruel to misgender trans people as a means of demonstrating disapproval. Doing so is a form of arrogance.

Misgendering is a false message that an individual's approval has been solicited (it has not). Then that individual feels compelled to demonstrate that their approval is withheld. It is entirely unnecessary.

Murphee and Cretella believe two things about me (and then some): They believe that, because I am gay, I am objectively disordered. Because I am Jewish they believe that I am destined to go to Hell.

I really do not care what they believe. If they call me a faggot kike that gets my attention. Belief and conduct are two different things.Is expecting people to be polite really so burdensome?

Referring to the construct of gender as separate from natal sex:

Again, if Cretella disagrees with the science then she should publish. Comments at one of AFA's outlets is not the equivalent of publishing to a reputable academic journal.

Cretella has never published because her views are based on religion in contrast to science. She is also a demagogue. No one is attacking children and children are not candidates for surgery. Furthermore, Cretella seeks to substitute her religious judgment for that of clinicians and parents.

Let us review what Cretella calls an attack. Prepubescent children transition if a) they are in distress and; b) if transitioning offers relief. Transitioning means gender-conforming clothes and hair. No drugs whatsoever.After entering puberty (Tanner stage 2 or 3) adolescents might be provided with puberty blockers which are fully reversible according to the Endocrine Society.

According to the Mayo Clinic, for children who have gender dysphoria, suppressing puberty might:

If an adolescent child stops taking GnRH analogues, puberty will resume.

The administration of hormones is not gratuitous chemistry. It requires a clinical evaluation, a mental health evaluation, informed consent and parental consent. Consent means a demonstrable understanding of risks and benefits.

A simple and simplistic comment triggers a verbose rebuttal but we all need to separate science from religious ideology.

Off into a land where reality is optional

Thats simply insane! Cretella exclaimed. Its contrary to reality and to a Judeo-Christian worldview. Sex is determined. Its not assigned. Its determined at fertilization. If you have a Y chromosome, you will go down the male pathway. If youre missing the Y chromosome, youll go down the female pathway.

Cretella is being dishonest. She knows perfectly well that sex assigned at birth is a means of communicating the difference between natal sex from gender. It is applicable to a very small percentage of the population.

A feeble attempt to claim that science is on their side

As adults, physical differences between men and women account for many of their contrasting thought patterns and behaviors, even if they agree in principle on important areas of life, e.g., parenting.

This all goes on for several paragraphs. Cretella uses the opportunity to take a dishonest swipe at marriage equality (which I will ignore) and there is this:

The worst side effects of puberty blocking may include brittle bones, obesity, testicular cancer, memory problems, and [if combined with cross-sex hormones] permanent sterilization, Cretella reported. This is child abuse.

Parents and the adolescent provide informed consent. They are aware of the potential side effects but make a considered judgment that the benefits outweigh the risks. Cretella has no experience in this area. Cretella has minimal training in endocrinology.

Notice how Cretella doesn't establish what that real help is. Children have rights too including the right to be treated according to the best available medical science.

Look! It's a bullshit kabob. Yum!

At long last the witch and her fluffer identify this as a religious issue

To declare that our bodies dont matter, she added, is diametrically opposed to Christian theology. The Incarnate Word. God how did He save? He saved us by taking on a human body. This is significant.

To believe our body is just this container, and it doesnt matter thats in line with reincarnation, Hinduism, Buddhism! It is the age-old conflict between a pagan worldview and a Christian one.

Related content:

Go here to read the rest:
Michelle Cretella is Back - Along With Her Sophistry - The Slowly Boiled Frog

Read More...

Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race – Raw Story

Saturday, April 25th, 2020

There is no scientific evidencethat the novel coronavirus was bioengineered, but its origins are not entirely clear. Deadly pathogens discovered in the wild can be studied in secret in biowarfare labs and sometimes made more dangerous. That possibility, and other plausible scenarios, have been incorrectly dismissed in remarks by some scientists andgovernment officials, and in the coverage of most major media outlets.

Regardless of the source of this pandemic, there is considerable documentation that a global biological arms race going on outside of public view could produce even more deadly pandemics in the future.

While much of the media and political establishment have minimized the threat from such lab work, some hawks on the American right like Sen. Tom Cotton, R-Ark., have singled outChinese biodefense researchers as uniquely dangerous.

But there is every indication that U.S. lab work is every bit as threatening as that in Chinese labs. American labs also operate insecret, and are also known to beaccident-prone.

The current dynamics of the biological arms race have been driven by U.S. government decisions that extend back decades. In December 2009, Reuters reported that the Obama administration was refusing even to negotiate the possible monitoring of biological weapons.

Much of the left in the U.S. now appears unwilling to scrutinize the origin of the pandemic or the wider issue of biowarfare perhaps because portions of the anti-Chinese right have been sovocal in making unfoundedallegations.

Governments that participate in such biological weapon research generally distinguish between biowarfare and biodefense, as if to paint such defense programs as necessary. But this is rhetorical sleight-of-hand; the two concepts are largely indistinguishable.

Biodefense implies tacit biowarfare, breeding more dangerous pathogens for the alleged purposeof finding a way tofightthem. While this work appears to have succeeded in creating deadly and infectious agents, including deadlier flu strains, such defense research is impotent in its ability to defend us from this pandemic.

The legal scholar who drafted the main U.S. law on the subject, Francis Boyle, warned in his 2005 book Biowarfare and Terrorism that an illegal biological arms race with potentially catastrophic consequences was underway, largely driven by the U.S. government.

For years,many scientistshave raised concerns regarding bioweapons/biodefense lab work, and specifically aboutthe fact that huge increases in funding have taken place since 9/11. This was especially true afterthe anthrax-by-mail attacks that killed five people in the weeks after 9/11, which the FBI ultimately blamed on a U.S. government biodefense scientist.A 2013 study found that biodefense funding since2001 hadtotaled at least $78 billion, and more has surely been spent since then. This has led to aproliferation of laboratories, scientists and new organisms, effectively setting off a biological arms race.

Following the Ebola outbreak in west Africa in 2014, the U.S. governmentpaused fundingfor what are known as gain-of-function research on certain organisms. This work actually seeks to make deadly pathogensdeadlier, in some cases making pathogens airborne thatpreviously were not. With little notice outside the field, the pause on such research was lifted in late 2017.

During this pause, exceptions for funding were made for dangerous gain-of-function lab work. This included work jointly done by U.S. scientists from the University of North Carolina, Harvard and the Wuhan Institute of Virology. This work which had funding from USAID and EcoHealth Alliance not originally acknowledged was published in2015 in Nature Medicine.

A different Nature Medicine article about the origin of the current pandemic,authored by five scientists andpublished on March 17,has been touted by major media outlet and some officials including current National Institutes of Health directorFrancis Collins as definitively disproving a lab origin for the novel coronavirus. That journal article, titled The proximal origin of SARS-CoV-2, stated unequivocally: Our analyses clearly show that SARS-CoV-2 is not a laboratory construct or a purposefully manipulated virus. This is a subtly misleading sentence. While the scientists state that there is no known laboratory signature in the SARS-Cov-2 RNA, their argument fails to take account of other lab methods that could have created coronavirus mutations without leaving such a signature.

Indeed, there is also thequestion of conflict of interest in the Nature Medicine article. Some of the authors of that article, as well as aFebruary 2020Lancet letter condemning conspiracy theories suggesting that COVID-19 does not have a natural origin which seemed calculated to minimize outside scrutiny of biodefense lab work have troubling ties to thebiodefense complex,as well as to the U.S. government. Notably, neither of these articles makes clear that a virus can have a natural originand then be captured and studied in a controlled laboratory setting before being let loose, either intentionally or accidentallywhichis clearly a possibility in the case of the coronavirus.

Facts as rumors

This reporter raised questions about the subject at a news conference with a Center for Disease Control (CDC) representative at the now-shuttered National Press Club on Feb. 11. I asked if it was a complete coincidence that the pandemic had started in Wuhan, the only place in China with a declared biosafety level 4 (BSL4) laboratory. BSL4 laboratories have the most stringent safety mechanisms, but handle the most deadly pathogens. As I mentioned, it was oddthat the ostensible origin of the novel coronavirus was bat caves in Yunnan province more than 1,000 miles from Wuhan. I noted that gain-of-function lab work can results in more deadly pathogens, and that major labs, including some in the U.S., have had accidental releases.

CDC Principal Deputy Director Anne Schuchat saidthatbased on the information she had seen, the virus was of zoonotic origin. She also stated, regarding gain-of-function lab work, that it is important to protect researchers and their laboratory workers as well as the community around them and that we use science for the benefit of people.

I followed up by asking whether an alleged natural origin did not preclude the possibility that this virus came through a lab, since a lab could have acquired a bat virus and been working on it. Schuchat replied to the assembled journalists that it is very common for rumors to emerge that can take on life of their own, but did not directly answer the question. She noted that in the 2014 Ebola outbreak some observers had pointed to nearby labs as the possible cause, claiming this was a key rumor that had to be overcome in order to help control the outbreak. She reiterated: So based on everything that I know right now, I can tell you the circumstances of the origin really look like animals-to-human. But your question, I heard.

This is no rumor. Its a fact: Labs work with dangerous pathogens. The U.S. and China each have dual-use biowarfare/biodefense programs. China has major facilities at Wuhan a biosafety level 4 lab and a biosafety level 2 lab. There are leaks from labs. (See Preventing a Biological Arms Race, MIT Press, 1990, edited by Susan Wright; also, a partial review in Journal of International Law from October 1992.)

Much of the discussion of this deadly serious subject is marred with snark that avoids or dodges the gain-of-function question. ABC ran a story on March 27 titled Sorry, Conspiracy Theorists. Study Concludes COVID-19 Is Not a Laboratory Construct.' That story did not address the possibility that the virus could have been found in the wild, studied in a lab and thenreleased.

On March 21, USA Today published a piece headlined Fact Check: Did the Coronavirus Originate In a Chinese Laboratory? and rated it FALSE.

That USA Today story relied ona widely cited Feb.17 piece inthe Washington Post, titled Tom Cotton keeps repeating a coronavirus conspiracy theory that was already debunked. That article quoted public comments fromRutgers University professor of chemical biology Richard Ebright, but out of context and only in part. Specifically, the story quoted from Ebrights tweet that the coronavirus was not an engineered bioweapon. In fact, his full quote included the clarification that the virus could have entered human population through lab accident. (An email requesting clarification sent toPost reporterPaulina Firoziwas met with silence.)

Bioengineered From a lab

Other pieces in the Post since then (some heavily sourced to U.S. government officials) have conveyed Ebrights thinking, but it gets worse. In a private exchange, Ebright who, again, has said clearly that the novel coronavirus was not technically bioengineered using known coronavirus sequences stated that other forms of lab manipulation could have beenresponsible for the current pandemic. This runs counter to much reporting, which is perhaps too scientifically illiterate to perceive the difference.

In response to the suggestion that the novel coronavirus could have come about through various methodsbesides bioengineering made by Dr. Meryl Nass, who has done groundbreaking work on biowarfareEbright responded in an email:

The genome sequence of SARS-CoV-2 has no signatures of human manipulation.

This rules out the kinds of gain-of-function (GoF) research that leave signatures of human manipulation in genome sequences (e.g., use of recombinant DNA methods to construct chimeric viruses), but does not rule out kinds of GoF research that do not leave signatures (e.g., serial passage in animals). [emphasis added]

Very easy to imagine the equivalent of the Fouchiers 10 passages in ferrets with H5N1 influenza virus, but, in this case, with 10 passages in non-human primates with bat coronavirus RaTG13 or bat coronavirus KP876546.

That last paragraph is very important. It refersto virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam, who performed research on intentionally increasing rates of viralmutation rate by spreading a virus from one animal to another in a sequence.The New York Times wrote about this in an editorial in January 2012, warning of An Engineered Doomsday.

Now scientists financed by the National Institutes of Health have created a virus that could kill tens or hundreds of millions of people if it escaped confinement, the Times wrote. The story continued:

Working with ferrets, the animal that is most like humans in responding to influenza, the researchers found that a mere five genetic mutations allowed the virus to spread through the air from one ferret to another while maintaining its lethality. A separate study at the University of Wisconsin, about which little is known publicly, produced a virus that is thought to be less virulent.

The word engineering in the New York Times headline is technically incorrect, sincepassing a virus through animals is not genetic engineering. This same distinction has hindered some from understanding the possible origins of the current pandemic.

Fouchiers flu work, in which an H5N1 virus was made more virulent by transmitting it repeatedly between individual ferrets, briefly sent shockwaves through the media. Locked up in the bowels of the medical faculty building here and accessible to only a handful of scientists lies a man-made flu virus that could change world history if it were ever set free, wrote Science magazine in 2011 in a story titled Scientists Brace for Media Storm Around Controversial Flu Studies. It continues:

The virus is an H5N1 avian influenza strain that has been genetically altered and is now easily transmissible between ferrets, the animals that most closely mimic the human response to flu. Scientists believe its likely that the pathogen, if it emerged in nature or were released, would trigger an influenza pandemic, quite possibly with many millions of deaths.

In a 17th floor office in the same building, virologist Ron Fouchier of Erasmus Medical Center calmly explains why his team created what he says is probably one of the most dangerous viruses you can make and why he wants to publish a paper describing how they did it. Fouchier is also bracing for a media storm. After he talked to ScienceInsider yesterday, he had an appointment with an institutional press officer to chart a communication strategy.

Fouchiers paper is one of two studies that have triggered an intense debate about the limits of scientific freedom and that could portend changes in the way U.S. researchers handle so-called dual-use research: studies that have a potential public health benefit but could also be useful for nefarious purposes like biowarfare or bioterrorism.

Despite objections, Fouchiers article was published by Science in June 2012. Titled Airborne Transmission of Influenza A/H5N1 Virus Between Ferrets, it summarized how Fouchiers research team made the pathogen more virulent:

Highly pathogenic avian influenza A/H5N1 virus can cause morbidity and mortality in humans but thus far has not acquired the ability to be transmitted by aerosol or respiratory droplet (airborne transmission) between humans. To address the concern that the virus could acquire this ability under natural conditions, we genetically modified A/H5N1 virus by site-directed mutagenesis and subsequent serial passage in ferrets. The genetically modified A/H5N1 virus acquired mutations during passage in ferrets, ultimately becoming airborne transmissible in ferrets.

In other words, Fouchiers research took a flu virus that did not exhibit airborne transmission, then infected a number of ferrets until it mutated to the point that it was transmissible by air.

In thatsame year, 2012, asimilar studyby Yoshihiro Kawaoka of the University of Wisconsin was published in Nature:

Highly pathogenic avian H5N1 influenza A viruses occasionally infect humans, but currently do not transmit efficiently among humans. Here we assess the molecular changes that would allow a virus to be transmissible among mammals. We identified a virus with four mutations and the remaining seven gene segments from a 2009 pandemic H1N1 virus that was capable of droplet transmission in a ferret model.

In 2014, Marc Lipsitch of Harvard and Alison P. Galvani of Yale wrote regarding Fouchier and Kawaokas work:

Recent experiments that create novel, highly virulent and transmissible pathogens against which there is no human immunity are unethical they impose a risk of accidental and deliberate release that, if it led to extensive spread of the new agent, could cost many lives. While such a release is unlikely in a specific laboratory conducting research under strict biosafety procedures, even a low likelihood should be taken seriously, given the scale of destruction if such an unlikely event were to occur. Furthermore, the likelihood of risk is multiplied as the number of laboratories conducting such research increases around the globe.

Given this risk, ethical principles, such as those embodied in the Nuremberg Code, dictate that such experiments would be permissible only if they provide humanitarian benefits commensurate with the risk, and if these benefits cannot be achieved by less risky means.

We argue that the two main benefits claimed for these experiments improved vaccine design and improved interpretation of surveillance are unlikely to be achieved by the creation of potential pandemic pathogens (PPP), often termed gain-of-function (GOF) experiments.

There may be a widespread notion that there is scientific consensus that the pandemic did not come out of a lab. But in factmany of the most knowledgeable scientists in the field are notably silent. This includes Lipsitch at Harvard, Jonathan A. King at MITand many others.

Just last year, Lynn Klotz of the Center for Arms Control and Non-Proliferation wrote a paperin the Bulletin of the Atomic Scientistsentitled Human Error in High-biocontainment Labs: A Likely Pandemic Threat. Wrote Klotz:

Incidents causing potential exposures to pathogens occur frequently in the high security laboratories often known by their acronyms, BSL3 (Biosafety Level 3) and BSL4. Lab incidents that lead to undetected or unreported laboratory-acquired infections can lead to the release of a disease into the community outside the lab; lab workers with such infections will leave work carrying the pathogen with them. If the agent involved were a potential pandemic pathogen, such a community release could lead to a worldwide pandemic with many fatalities. Of greatest concern is a release of a lab-created, mammalian-airborne-transmissible, highly pathogenic avian influenza virus, such as the airborne-transmissible H5N1 viruses created in the laboratories of Ron Fouchier in the Netherlands and Yoshihiro Kawaoka in Madison, Wisconsin.

Crazy, dangerous

Boyle, a professor of international law at the University of Illinois, has condemned Fouchier, Kawaoka and others including at least one of the authors of the recent Nature Medicine article in the strongest terms, calling such work a criminal enterprise. While Boyle has been embroiled in numerous controversies, hes been especially dismissed by many on this issue. The fact-checking websiteSnopeshas described him as a lawyer with no formal training in virology without noting that he wrote the relevant U.S. law.

As Boyle saidin 2015:

Since September 11, 2001, we have spent around $100 billion on biological warfare. Effectively we now have an Offensive Biological Warfare Industry in this country that violates theBiological Weapons Conventionand myBiological Weapons Anti-Terrorism Act of 1989.

The law Boyle drafted states: Whoever knowingly develops, produces, stockpiles, transfers, acquires, retains, or possesses any biological agent, toxin, or delivery system for use as a weapon, or knowingly assists a foreign state or any organization to do so, shall be fined under this title or imprisoned for life or any term of years, or both. There is extraterritorial Federal jurisdiction over an offense under this section committed by or against a national of the United States.

Boyle also warned:

Russia and China have undoubtedly reached the same conclusions I have derived from the same open and public sources, and have responded in kind. So what the world now witnesses is an all-out offensive biological warfare arms race among the major military powers of the world: United States, Russia, Britain, France, China, Israel, inter alia.

We have reconstructed the Offensive Biological Warfare Industry that we had deployed in this county before its prohibition by the Biological Weapons Convention of 1972, described by Seymour Hersh in his groundbreaking expose Chemical and Biological Warfare: Americas Hidden Arsenal. (1968)

Boyle now states that he has been blackballed in the media on this issue, despite his having written the relevant statute. The group he worked with on the law, the Council for Responsible Genetics, went under several years ago, making Boyles views against biodefense even more marginal as government money for dual use work poured into the field and criticswithin the scientific community have fallen silent. In turn, his denunciationshave grown more sweeping.

In the 1990 book Preventing a Biological Arms Race, scholar Susan Wright argued that current laws regarding bioweapons were insufficient, as there were projects in which offensive and defensive aspects can be distinguished only by claimed motive. Boyle notes, correctly, that current law he drafted does not makean exception for defensive work, but only for prophylactic, protective or other peaceful purposes.

While Boyle is particularly vociferous in his condemnations, he is not alone. There has been irregular, but occasional media attention to this threat. The Guardian ran a piece in 2014,Scientists condemn crazy, dangerous creation of deadly airborne flu virus, afterKawaoka created a life-threatening virus that closely resembles the 1918 Spanish flu strain that killed an estimated 50m people:

The work they are doing is absolutely crazy. The whole thing is exceedingly dangerous, said Lord May, the former president of the Royal Society and one time chief science adviser to the UK government. Yes, there is a danger, but its not arising from the viruses out there in the animals, its arising from the labs of grossly ambitious people.

Boylescharges beginning early this yearthat the coronavirus was bioengineered allegationsrecently mirrored by French virologist andNobel laureate Luc Montagnier have not been corroborated by any publicly produced findings of any U.S. scientist. Boyle even charges that scientists like Ebright, who is at Rutgers, arecompromised because the university got abiosafety level 3 lab in 2017though Ebright is perhaps the most vocal eminent critic of this research, among U.S. scientists. These and other controversies aside, Boyles concerns about the dangers of biowarfare arelegitimate; indeed, Ebright shares them.

Some of the most vocal voices to discuss the origins of the novel coronavirushave been eager to minimizethe dangers of lab work, or have focused almost exclusively on wet markets or exotic animals as the likely cause.

The media celebrated Laurie Garrett, the Pulitzer Prizewinning author and former senior fellow at the Council on Foreign Relations, when she declared on Twitter on March 3 (in a since-deleted tweet)that the origin of the pandemic was discovered: Its pangolins. #COVID19 Researchers studied lung tissue from 12 of the scaled mammals that were illegally trafficked in Asia and found #SARSCoV2 in 3. The animals were found in Guangxi, China. Another virus+ smuggled sample found in Guangzhou.

She was swiftly corrected by Ebright: Arrant nonsense. Did you even read the paper? Reported pangolin coronavirus is not SARS-CoV-2 and is not even particularly close to SARS-CoV-2. Bat coronavirus RaTG13 is much closer to SARS-CoV-2 (96.2% identical) than reported pangolin coronavirus (92.4% identical). He added: No reason to invoke pangolin as intermediate. When A is much closer than B to C, in the absence of additional data, there is no rational basis to favor pathway A>B>C over pathway A>C. When someone asked what Garrett was saying, Ebright responded: She is saying she is scientifically illiterate.

The following day, Garrett corrected herself (without acknowledging Ebright): I blew it on the #Pangolins paper, & then took a few hours break from Twitter. It did NOT prove the species = source of #SARSCoV2. Theres a torrent of critique now, deservedly denouncing me & my posting. A lot of the critique is super-informative so leaving it all up 4 while.

At leastone Chinese governmentofficialhas respondedto the allegation that the labs in Wuhan could be the source for the pandemic by alleging that perhaps the U.S. isresponsibleinstead. In American mainstreammedia, that has been reflexivelytreated as evenmore ridiculousthan the original allegation that the virus could havecome froma lab.

Obviouslythe Chinese governmentsallegations should not be taken at face value, but neither should U.S. government claims especially considering that U.S. government labs were the apparent source for theanthrax attacks in 2001. Those attacks sent panic through the U.S. and shut down Congress, allowing the Bushadministration to enact the PATRIOT Act and ramp up the invasions of Afghanistan and Iraq. Indeed, in October2001, media darlings like Richard Butler and Andrew Sullivan propagandizedfor war with Iraq because of the anthrax attacks. (Although it turned out that neither Iraq nor al-Qaida was involved.)

The 2001 anthrax attacks also provided muchof the pretext forthe surge in biolab spending since then, even though they apparently originated in a U.S. or U.S.-allied lab. Indeed, thoseattacks remain shrouded in mystery.

The U.S. government has also come up withelaborate cover stories to distract from its bioweapons work. For instance, the U.S. government infamously claimed the 1953 death of Frank Olson, a scientist at Fort Detrick, Maryland, was anLSD experiment gone wrong;it now appears to have been an execution to cover up for U.S.biological warfare.

Regardless of the cause of the current pandemic, these biowarfare/biodefense labs need far more scrutiny. The call to shut them down by Boyle and others needs to be clearly heard and light must be shone on precisely what research is being conducted.

The secrecy of these labs may prevent us ever knowing with certainty the origins of the current pandemic. It could have been a lab release, presumably accidental, or it could have been a zoonotic, or animal-to-human, infection

What we do know is this lab work comes with real dangers. One might make a comparison to climate change: We cannot attribute an individual hurricane to man-made climate disruption,yet science tells us that human activity makes stronger hurricanes more likely. Thatbrings us back to the imperative to cease the kinds of activities thatproduce such dangers in the first place.

If that doesnt happen, the people of the planet will be at the mercy of the machinations and mistakes of state actors who are playing with fire for their geopolitical interests.

Sam Husseini is a writer and political activist. He is communications director of the Institute for Public Accuracy, a Washington-based nonprofit that promotes progressive experts as alternative sources for mainstream media reporters. He tweets @samhusseini.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we here at Raw Story believe in the power of progressive journalism. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and legal efforts to harm workers exploited by abusive bosses. And unlike other news outlets, weve decided to make our original content free. But we need your support to do what we do.

Raw Story is independent. Unhinged from corporate overlords, we fight to ensure no one is forgotten.

We need your support in this difficult time. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you. Click to donate by check.

then let us make a small request. The COVID crisis has cut advertising rates in half, and we need your help. Like you, we believe in the power of progressive journalism and were investing in investigative reporting as other publications give it the ax. Raw Story readers power David Cay Johnstons DCReport, which we've expanded to keep watch in Washington. Weve exposed billionaire tax evasion and uncovered White House efforts to poison our water. Weve revealed financial scams that prey on veterans, and efforts to harm workers exploited by abusive bosses. We need your support to do what we do.

Raw Story is independent. You wont find mainstream media bias here. Every reader contribution, whatever the amount, makes a tremendous difference. Invest with us in the future. Make a one-time contribution to Raw Story Investigates, or click here to become a subscriber. Thank you.

Read the rest here:
Did this virus come from a lab? Maybe not but it exposes the threat of a biowarfare arms race - Raw Story

Read More...

I’m Sorry, What? – Outside The Beltway – Mobile Edition

Saturday, April 25th, 2020

Trump made some odd suggestions on today's Al Presidente.

Steven L. Taylor Thursday, April 23, 2020 82 comments

Bloomberg reports: Trump Sees Coronavirus Hope in Summer, Sunlight and Bleach

The virus is dying at a much more rapid pace from exposure to humidity or heat, Bill Bryan, an undersecretary at the Homeland Security Department, said at a White House news conference on Thursday.

[]

Bryan suggested the new U.S. research offered practical tips for many Americans, including increasing the temperature and humidity for potentially contaminated indoor spaces in order to kill the virus on surfaces. At a temperature of 70 to 75 degrees Fahrenheit and 80% humidity in the summer sun, for example, the research showed the virus would last just two minutes on a porous surface. Dry environments Bryan said, may require extra care.

Very Powerful Light

Trump appeared intrigued by the research after Bryans presentation.

Suppose we hit the body with a tremendous ultraviolet or just very powerful light, Trump said, following Bryans presentation. I think that hasnt been checked but youre going to test it.

Researchers could also bring the light inside the body Trump said, either through the skin or in some other way.

[]

Bryan also said that research had shown bleach could kill the virus in saliva or respiratory fluids in five minutes and isopropyl alcohol could kill it even more quickly. Trump suggested there would be more testing there, too.

The disinfectant knocks it out in a minute. One minute, he said. Is there a way we can do something like that by injection inside? He said it would be almost a cleaning. It gets in the lungs and does a tremendous number on the lungs.

(Emphases mine).

In case you cant believe what you just read:

I am not sure which is crazier, the notion that cleaner could be used or light could be put inside the body (although, really, does one have to rank in this case?).

Unlike the President of the United States, the Bloomberg report cautions:

Disinfecting surfaces is an important practice in infection control. The coronavirus is fragile outside the body, and is essentially a packet of genetic information wrapped in a packet of lipids. Hand washing with soap is particularly effective in cleaning it and stopping transmission.

The U.S. Centers for Disease Control and Prevention has warned Americans to be careful with cleaning products in their rush to use cleaners and disinfectants, which have been snapped up from store shelves and are still hard to find at many retailers. Poisonings related to cleaners and disinfectants rose significantly in March, according to the CDC. In one case, a woman was sent to the hospital after filling her sink with bleach solution, vinegar and hot water to soak her vegetables.

He tries to bring Birx into the mix and then note his response when confronted about the whole heat and light thing:

You know, hes just asking. Lighten up!

All of this is, of course, quite bizarre and I am leaning heavily on the absurdity angle (as this is very much a laugh lest you cry situation). But, good grief, we in the middle of a global pandemic with no clear end in sight and with over 44,000 Americans dead, and the president is spitballing light therapy and the potential use of cleaners in the human body to fight Covid-19. And worse, many, many of my fellow Americans think he is doing a good job.

BTW, if we think that heat and humidity will be our salvation, the following story popped up while I was writing this (via the NYT): Ecuadors Death Toll During Outbreak Is Among the Worst in the World.

With bodies abandoned on sidewalks, slumped in wheelchairs, packed into cardboard coffins and stacked by the hundreds in morgues, it is clear that Ecuador has been devastated by the coronavirus.

But the epidemic is even worse than many people in the country realize.The death toll in Ecuador during the outbreak was 15 times higher than the official number of Covid-19 deaths reported by the government, according to an analysis of mortality data by The New York Times.The numbers suggest that the South American country is suffering one of the worst outbreaks in the world.

[]

There has been a surge of infections in the province that includes Ecuadors business capital, Guayaquil, where residents are thought to have brought the virus home after visiting Spain.In Guayaquil, fatalities during the first two weeks of April were eight times higher than usual, the data indicates a far greater rise than that of New York City, where fatalities were four times higher in recent weeks.

Guayaquil has a decidedly tropical climate

PS. Yes, the use of light to kill an infestation was a plot point in the Star Trek TOS episode, Operation: Annihilate:

Read more:
I'm Sorry, What? - Outside The Beltway - Mobile Edition

Read More...

Why biotech’s goal should not be to feed the world – SynBioBeta

Saturday, April 25th, 2020

Its a great moment for big food, big ag, and industry to do a self reflection and analysis of, how did we arrive here? How did we arrive to a world where the folks that picked the produce out of the field dont have access and or make enough to buy the very produce that theyre picking? Rolando Perez, graduate student and volunteer at Xinampa

Biotechnology is on the precipice of changing our world forever. Using solutions always there in biology and optimizing them with technology, biotech promises to solve global issues such as carbon emissions, plastic and chemical pollution, and, of course, feeding a booming population. But to really solve the issue of food, the industry needs to revolutionize more than just biology or technology. It needs to revolutionize the way it engages local cultures and economies. It will not be an easy task, a straightforward task, or a quick task. But it can be done and the people of the world depend on it being done right.

Climate change and population growth have led to predictions that the global population will reach nearly 10 billion people by 2050. Current food production processes cant keep pace with that growth. Fearing an existential crisis, several companies have adopted a tag line that goes something like this: we will feed the world through innovative biotechnologies that are more sustainable and make healthy food more accessible. And theyve got the sustainability beat down: from leveraging microbes to feed plants and reduce toxic nitrogen run-off to improved aquaculture techniques to genetic engineering foods to be more nutritious, the possibilities for producing ever more nutritious food while using less of the Earths precious resources are boundless and already in motion.

But what, exactly, does it mean for food to be accessible in todays world?

Food desert a term used to describe areas with limited access to affordable and nutritious food is the label by which weve come to describe food accessibility today. But the term is a bit of a misnomer, says Garrett Broad, author of More Than Just Food.

It suggests theres nothing there and if food deserts are the problem, the solution sounds pretty simple: just bring [stuff] to the desert.

But is there really nothing there? According to a recent New York Times exposition on the obesity epidemic in Brazil (and in big industrys role in that), there are now more obese people in the world than underweight people. Its as if the pendulum has swung the other direction where hunger was once a very real problem as a result of access to food, period, now obesity, diabetes, and heart disease prevail as a result of access to high calorie, nutrient-poor foods. This has created a new type of malnutrition, write Andrew Jacobs and Matt Richtel, one in which a growing number of people are both overweight and undernourished.

So, continues Broad, the problem isnt food deserts [per se], the problem is really a legacy and generational disinvestment in and direct discrimination in not just food but in a variety of other arenas. [This] calls for a broader set of solutions.

Said another way, the issue of food accessibility is multi-faceted and therefore cannot be solved solely through biotechnology we must come to terms with that fact at the get go. That isnt to say biotechnology cant make the food production system as a whole better. With advances in gene editing and other technologies, we can use technology to improve the nutritional profile of food (tackling malnutrition), to enable seasonable crops to be available all year round (increasing accessibility in one sense), to remove undesired characteristics such as cherry pits (increasing accessibility in another sense), and to make food more resistant to drought, one of the biggest factors influencing a significant proportion of the world populations access to food. But none of this matters if we keep operating under our current system, which, according to Broad, bottom-lines on profit margins, not on feeding people healthily and sustainably.

The biotechnological revolution can give the food industry and low-income disadvantaged communities a chance to hit the reset button to learn from the current state of affairs and prevent the inevitable shortfall of the big promises being made by biotechnology today if we dont change the societal, political, and economic backbone of the way food is made and distributed. And according to Ana Ibarra and Rolando Perez, volunteers at Salinas Valley-based Xinampa (a bio-hub aiming to support equitable economic development, workforce development, small business incubation, and scientific literacy and education), such sea change will come from getting people from all walks of life to sit down together and talk.

From left: Steven Rhyans, Anna Ibarra-Castro, Leo Tejeda, Omar Perez, Matias Kaplan, Rolando Perez. Photo credit: Steven Rhyans

Many of the communities most affected by food inequality are disadvantaged, underrepresented cultural and ethic groups, such as the Hispanic/Latinx and indigenous populations served by Xinampa. Salinas, California, where Xinampa is based, is over 75% Hispanic or Latinx and it is this population that is the life blood of one of the richest agricultural areas in the world. Xinampa is especially passionate about teaching young people high school and college students how they can use biotechnology in their future careers and to bolster their local communities. Ibarra says that young people will be critical for speeding up the development of technologies, a crucial goal given the issues we have at a global scale to sustain human life in light of climate change, decreasing arable land. The younger generations have the ability and talent to carry this forward, she says, and I believe its crucial to start engagement at a young age.

But, Perez is careful to point out, it isnt just about reaching the young.

The work here is intergenerational, and thats really important. There has to be engagement across the whole intergenerational spectrum the bio belt could be about finding opportunities for retirees to do things in the community plant gardens that produce nutritious produce for the community, for example. The next generation is like the seventh generation. You can say seven generations in the future, seven generations in the past, or you can strategically place yourself in the middle of those seven generations; something I learned from a close friend and that has helped me understand my role as a community member and citizen of our planet.

Emphasizing culture and recognizing that the community as a whole, and in particular indigenous communities, has deep-seeded, critical knowledge about agriculture is a core value of Xinampa. Instead of feeding people the all-too-often heard script of you guys just dont know anything, youre eating unhealthy, and were here to change you, they recognize and encourage the generations of knowledge and cultural richness that will be critical for effectively governing and incorporating biotechnology into our future food systems.

What the most successful groups that work around food at the grassroots level do is they push past those scripts, and they open up some storytelling about peoples cultural histories through food, says Broad, and that allows folks to claim knowledge about food and cooking and agriculture, which makes them much more likely to have ownership in this whole conversation.

And the whole conversation must also engage policy makers, those involved in the public health care system, industry leaders essentially anyone that could be affected by biotechnology.

One of the solutions that we could employ to address these inequities is to look to the expertise of individuals in public health, policy, social welfare, or other disciplines that are exposed to issues through a different lens and can provide a different point of view, says Ibarra, adding that its important to foster interdisciplinary conversation early on. We dont want to miss something. We dont want to invest in a solution that may not be the most effective simply because you forgot to include someone in the conversation. Early engagement is how these nutritious and novel foods will be cultivated from the ground up for the benefit of everyone in society.

One of the reasons early involvement in conversation will enable effective distribution of food to everyone is rooted in money. According to Broad, one of the biggest reasons why mistrust in GMOs and how GMO foods could solve some big problems isnt because companies havent been transparent. Its because people look at the big players, the companies in charge, and see companies that havent made their lives substantively better. People recognize that priorities within the biotech industry have not necessarily always been first and foremost about feeding the world equitably and sustainably but instead about who profits from certain biotechnological developments, says Broad. This erodes trust rather than building it.

A great way to build long standing trust is to have equitable distribution of the material wealth that gets created from these innovations. Essentially, how do we think about the development of these tools in an equitable and inclusive way in terms of economic development and economic opportunity? The best way to do this is to get people involved from early on and give them an economic stake so you develop companies that people are engaged in and involved in. That would be something for entrepreneurs and communities like [SynBioBeta] to be thinking about from an early stage, as opposed to thinking about it as kind of a PR approach that comes at the very end.

Its the economy stupid, he continues. Its that classic line if people can see that their economic and social life is going to benefit from these new innovations, then theyre much more likely to be interested in supporting them and have less fear, he says.

Ibarra agrees.

There is a lot of fear around automation and AI, including in communities like ours where the fear is robots are going to come in and pick produce and there will be less jobs for our laborers, she says. But I think the opportunities deriving from biotechnology have an even greater potential. In Monterey County we have a very robust economy resulting from direct and indirect agricultural jobs, but also a significant multiplier effect. If we couple new agricultural technologies, such as automation and AI, with biotechnology in parallel, you can see this allowing communities especially rural ones to be more resilient. Its a real opportunity.

This is critical for communities like Salinas Valley, where homelessness rates in elementary schools can be as high as 50 percent. According to Ibarra, agricultural communities like Salinas are the perfect place to cultivate regenerative biotechnologies that enrich our food systems and advance public health. She and Perez imagine a future for Salinas Valley completely transformed by biotechnology rooted in racial and class equity and justice. For example, Central Coast residents could create public interest biotechnologies that emphasize community control and governance, with investment in people, infrastructure, automation, and supply-chains that extend into the community and that connect to the Valleys world-class global supply-chains. Biotechnology can also be leveraged to produce nutritious crop varieties that adapt plant morphology to make harvesting by hand easier or gene drives to combat invasive pests such as the Asian Citrus Psyllid. Animal agriculture could benefit as well, with new veterinary biotechnological tools to better care for livestock and protect them from disease. Water systems could benefit as well, from cleaning the Salinas River through mycoremediation to employing biosensors to monitor city water for pollution, pesticides, and other chemicals.

In December 2019, Golden Rice was approved for direct use in the Philippines the first Asian country to grant the controversial food approval. Some expect that the added Vitamin A present in the rice will reduce by up to 50% vitamin A deficiency, the leading cause of child mortality in the country. But, others are skeptical that the rice will be the simple solution Filipinos have been waiting for, pointing out that vitamin A deficiency is a complex problem partially rooted in culture, political economics, education, and access. In essence, Golden Rice is the perfect example of both the promise of biotechnology in agriculture and its shortcomings if we dont think critically about all sides of the issue. With up and coming companies like Pairwise Plants and others using biotechnology to produce food that is more nutritious and can be available year-round, it is critical that we heed voices like Broad, Ibarra, and Perez so that technologies that can really make a difference in how we feed the world dont meet the same fate as Golden Rice.

It is possible to feed the world with biotechnology. But its only possible if our goal isnt to feed the world, but to engage local communities, support early, equitable, and inclusive communication, and to ensure that food equity doesnt just mean that everyone can afford to buy healthy food, but that the communities producing that food have equitable economic stake. Move over, big ag its time to take biotechnology from farm to table.

Read the original post:
Why biotech's goal should not be to feed the world - SynBioBeta

Read More...

Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 – Cole of Duty

Saturday, April 25th, 2020

The Chromatography in Pharmaceuticals and Biotechnology Market report shows a brilliant presentation of regional growth, competition and provides accurate statistics with price and gross margin and other essential factors to grow in the Chromatography in Pharmaceuticals and Biotechnology market. The Chromatography in Pharmaceuticals and Biotechnology market report digs deep into critical aspects of key subjects which help market players to make appropriate changes in their approach and help you craft better strategies. The report is made with a combination of detailed information relying upon the important data researched by our analysts.

Chromatography is a continuously evolving technique, and its success is dependent on the innovations in technology. Therefore, this report discusses the emerging trends in chromatography technology, particularly the instruments and the reagents. It also features the new developments and new product launches in the global market.

The report provides relevant patent analyses and comprehensive profiles of market players in the industry. The Industry Structure chapter focuses on the important chromatography instruments and reagent manufacturers and suppliers, their market shares and product offerings. The chapter also covers the mergers and acquisitions and any other collaborations or partnerships that happened during the evaluation period of this report that are expected to shape the industry.

BCCs new report on chromatography elaborates on the strengths, weaknesses, threats and opportunities of the global chromatography market. Any regulatory changes or new initiatives are also highlighted.

Get Sample Copy of this Report @https://www.reportsintellect.com/sample-request/698611

Chromatography in Pharmaceuticals and Biotechnology Market report provides competitive analysis which helps clients to become aware of the unique characteristics of crucial factors impacting the market competition and hence changing their growth potential by manifold. Chromatography in Pharmaceuticals and Biotechnology market report provides accurate market data, market dynamics, and key segments.

Get Discounted Report @https://www.reportsintellect.com/discount-request/698611

Table of Contents:-

Highlights of the worldwide Chromatography in Pharmaceuticals and Biotechnology Market Report:

About us:

Reports Intellect provides research reports for everything related to market research and market intelligence. We understand the importance of the market with its needs in todays competitive world.

Our team works to obtain the most authentic research reports, accompanied by perfect data figures which guarantee exceptional results for you and your company every time.

Our team is there to help you in the best possible way, whether it is the latest report from the researchers or a personalized requirement, do not hesitate to contact us.

Contact us:

[emailprotected]

PH + 1-706-996-2927

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

The rest is here:
Chromatography in Pharmaceuticals and Biotechnology Expansion ( COVID 19-UPDATED ) Projected to Gain an Uptick During 2026 - Cole of Duty

Read More...

Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 – Bandera County Courier

Saturday, April 25th, 2020

Mrinsights.bizhas published a new report titled GlobalAnimal Stem Cell TherapyMarketGrowth 2020-2025 which comprises new statistical data on the changing market scenario and initial and future assessment of the market. The report covers a wide range of business aspects global Animal Stem Cell Therapy trends, future forecasts, growth opportunities, key end-user industries, and market players. The report analyzes the recent developments, investment opportunities, and probable threats in the market. It closely looks at the markets all-purpose evaluation and depicts the important data associated with the global market.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/232664/request-sample

The report assesses the demand-side and supply-side trends in the global Animal Stem Cell Therapy market. Various segments are scrutinized that involve end-users, regions, and players on the basis of demand patterns, and prospect for 2020 to 2025 time-period. The research report contains a comprehensive database on future market estimation based on historical data analysis. Key players are listed with major collaborations, mergers & acquisitions and upcoming and trending innovation. Primary research involves interviews, news sources and information booths. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

Understanding The Competitive Scenario:

Competitive landscape analysis is presented which involves the global Animal Stem Cell Therapy market share of major players, along with the new projects and strategies adopted by players in the past five years. Comprehensive company profiles comprise the product offerings, key financial information, recent developments, SWOT analysis, capacity, production, price, revenue, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, and strategies employed by the major market players. Additionally, the report covers insights into the production and capacities in terms of manufacturing with price fluctuations of raw materials, process in-flow rate product cost, and production value.

Considering market analysis, the profiled list of companies in the report is:Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA, U.S. Stem Cell, Inc, VetCell Therapeutics, J-ARM, Kintaro Cells Power, Celavet Inc., Animal Stem Care, Magellan Stem Cells, Cell Therapy Sciences, Animacel

Currently, the research report gives special attention and focus on the following regions:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Moreover, the report identifies potential customers and suppliers as well as gives an analysis of the companys business structure, operations, major products and services, and business strategy. The study helps you understand the companys core strengths, weaknesses, opportunities, and threats. The report shows factual data about the global Animal Stem Cell Therapy market in the worldwide area, for example, production chain, manufacturing capacity, sales volume, and revenue.

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-animal-stem-cell-therapy-market-growth-2020-2025-232664.html

The Scope of The Global Animal Stem Cell Therapy Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

The rest is here:
Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 - Bandera County Courier

Read More...

Page 8«..78910..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick